Business Wire

CGTN

11.6.2020 05:37:05 CEST | Business Wire | Press release

Share
CGTN: How China's Top-down Command System Helped Contain COVID-19?

China’s centralized and efficient command system formed a strong guarantee for the country to win the all-out people's war against COVID-19, according to a recently-released government white paper.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200610005922/en/

The document released on June 7 chronicled China's battle against COVID-19, detailing its painstaking yet effective efforts to control the outbreak domestically and its swift responses to contain the spread globally.

The coronavirus caught China unaware, the white paper noted, but the Chinese government acted swiftly to fight the virus and provide medical treatment for patients, prioritizing people's lives and health.

Since the first cases were detected in late December 2019, China has adopted thorough, rigorous and comprehensive prevention and control measures, as well as enforced quarantine and isolation, on a scale never seen before.

Medical resources have been mobilized across the country, and all those in need have been tested, quarantined, hospitalized or treated. With these measures in place, the country was able to contain the outbreak quickly and prevent a wider spread.

The white paper divides China's fight against the epidemic into five stages – "swift response" (December 27, 2019 to January 19, 2020), "initial containment" (January 20 to February 20), "single-digit increase in new domestic cases" (February 21 to March 17), "initial victory in a critical battle" (March 18 to April 28) and "epidemic control, new normal" (from April 29 onwards).

Timeline: China's fight against COVID-19 in five stages

Graphics: Inside China's all-out effort to contain the coronavirus

It took China more than three months to declare an initial victory in the COVID-19 battle, according to the white paper. This was possible as a result of the country's centralized and highly efficient command system, the white paper concluded.

Under the strong leadership of the CPC Central Committee with Xi Jinping at its core, central authorities exercise overall command while local authorities and all sectors follow the leadership and instructions of the central authorities, perform their respective duties and cooperate with each other.

President Xi assumed full command over the control efforts from the beginning of the outbreak. He chaired 14 meetings of the Standing Committee of the Political Bureau of the CPC Central Committee, four meetings of the Political Bureau, meetings of the Central Commission for Law-based Governance, Central Cyberspace Affairs Commission, Central Commission for Further Reform, and Central Commission for Foreign Affairs, and a meeting with prominent non-CPC figures. At these meetings, he heard briefings about epidemic prevention and control work and made decisions on overall plans for strengthening control efforts and international cooperation.

The president inspected community response and COVID-19 research in Beijing, and visited Wuhan to guide the frontline response. He has also inspected Zhejiang, Shaanxi, Shanxi and Gansu provinces, where he was briefed on progress in coordinating epidemic prevention and control with economic and social development, as well as in poverty alleviation.

Meanwhile, the central government coordinated the epidemic control work. Premier Li Keqiang, as head of the Central Leading Group for Novel Coronavirus Prevention and Control, chaired more than 30 meetings regarding COVID-19 control and economic resumption.

On January 7, Xi issued instructions on epidemic prevention and control work when he chaired a meeting of the Standing Committee of the Political Bureau of the CPC Central Committee.

On January 23, Wuhan, a megacity with a population of more than 10 million, was locked down in an unprecedented effort to contain the spread of the virus.

The central government mobilized medical experts and supplies as well as provisions for daily living needs such as food and energy to assist Wuhan and Hubei, and major public health emergency responses were activated across the country.

On January 25, the Standing Committee of the Political Bureau of the CPC Central Committee set up a central leading group on the epidemic, dispatched a central guiding team and demanded a State Council inter-agency task force play a full role in coordination.

The central leading group went to Wuhan to inspect and direct prevention and control of COVID-19 on January 27. Premier Li, who headed the leading group, also went to Wuhan to inspect the front lines.

In meetings with the CPC's senior leaders in early February, Xi called for measures to implement higher admission and treatment rates and lower infection and fatality rates. He also asked governments at all levels to implement targeted policies to contain the outbreak quickly.

Official data showed that many provinces started to lower their major public health emergency response levels from February 21, indicating the COVID-19 outbreak was coming under control.

On March 11, daily new domestic cases fell to single digits for the first time on the Chinese mainland. A week later, the mainland reported no increase in domestic cases for the first time.

As China declared an early victory in the containment of COVID-19 and normalized epidemic prevention and control, the CPC's top leadership made arrangements to steadily lift the travel restrictions and open up economic activity.

On May 7, the central government issued guidelines on normalized epidemic prevention and control.

Link:

ClickThru

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release

Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release

The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye